Business Wire

Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”

29.6.2026 13:00:00 EEST | Business Wire | Press release

Share

Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path.

What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large.

Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career to the world’s most prestigious stages, he has followed a path shaped by conviction and the courage to go beyond what the world believed he could be.

The evolution of Philip Morris International reflects the same structure, driven by early decisions, sustained commitment and the discipline to deliver change over time. Today, that transformation is measurable: smoke-free products account for 43% of PMI’s net revenues and reach consumers in over 105 markets worldwide as of first-quarter 2026.

“We committed to transform our business, replacing cigarettes with better alternatives because it was the right thing to do and because we could. There was no Plan B,” said Massimo Andolina, President Europe Region, Philip Morris International. “Today, we launch our partnership with Andrea Bocelli in Venice, the city of bridges, to raise awareness of what technology and innovation can make possible and showing that this progress is already real.”

I have always believed in the importance of staying true to one’s values and embracing each step of the journey, learning along the way,” said Maestro Andrea Bocelli. “We must consider possible even what may seem impossible, when it helps improve lives and advance human progress.

Designed to engage cultural, institutional and business audiences across Europe, “Believe. Further” will evolve over time, expanding its reach as the conversation around progress continues. It reflects a shared approach towards the future, and a shared belief that progress matters and is the only direction worth choosing.

Media Information: www.believefurther.com

Philip Morris International: A Global Smoke-Free Champion

Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch, and e-vapor products. Our smoke-free products are available for sale in over 105 markets, and as of December 31, 2025, PMI estimates they were used by over 43 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 43% of PMI’s first-quarter 2026 total net revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match’s General snus and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumablesand General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas. References to “PMI”, “we”, “our” and “us” mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.

About Maestro Andrea Bocelli

Maestro Andrea Bocelli is one of the most celebrated tenors in the world, recognized globally for his distinctive voice, artistic range, and ability to connect audiences across cultures and generations.

Born in Lajatico, Tuscany, Andrea Bocelli is an Italian tenor celebrated worldwide for his singular ability to bridge the worlds of opera and popular music. Over a career spanning four decades, he has sold more than 90 million records and generated over 16 billion streams - figures that place him among the most listened to classical artists in recorded history. His journey reflects a path shaped by choice, discipline, and a deep commitment to his craft.

He studied law at the University of Pisa, qualified as an attorney, and only then followed the deeper call of music - training under the great tenor Franco Corelli and building, note by note, one of the most distinctive voices of his generation. His reach extends far beyond the concert hall. He has performed at the coronation of King Charles III, sung at the 75th anniversary of the Italian Constitution before the President of Italy, and brought his voice to audiences across five continents. He performed at the opening ceremony of the 2026 Winter Olympics in Milan - a moment that placed him, once again, at the center of global culture. In 2011, Bocelli and his family established the Andrea Bocelli Foundation, whose mission is to empower people and communities facing poverty, illness, and social exclusion - giving expression to the belief that we can do much alone, but far more together. It is this conviction - that art carries responsibility, that beauty has a duty, and that progress is not measured in records sold but in lives touched - that makes Maestro Bocelli a natural and defining voice in this initiative.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260629494181/en/

Contacts

Philip Morris International
Radoslav Hristov
T: +41 (76) 394 45 66
E: radoslav.hristov@pmi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MANE Selects Kinaxis to Strengthen Global Planning Capabilities29.6.2026 14:00:00 EEST | Press release

Kinaxis®(TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that MANE, one of the top five leading organizations worldwide in the flavours and fragrances industry, has selected Kinaxis to modernize its planning capabilities as it accelerates global growth as part of a broader enterprise-wide transformation initiative. Headquartered in the south of France, with a significant global footprint spanning multiple regions and customers across international markets, MANE is known for its innovation, technical expertise and strong commitment to sustainability. The company is investing in more connected, end-to-end planning capabilities to support continued growth and increasing operational complexity worldwide. Following an extensive evaluation process with major competitors in the market, MANE selected the Kinaxis Maestro platform for its proven ability to support complex, multi‑region planning environments with speed, transparency, and confidence

From Abu Dhabi to Imola: A2RL Expands Internationally with Historic Autonomous Racing Debut at Iconic Italian Track29.6.2026 13:12:00 EEST | Press release

The Abu Dhabi Autonomous Racing League, A2RL, will make its international racing debut on 5 September 2026 in Imola, Italy, bringing up to 5 fully autonomous racecars based on the Dallara Super Formula SF23 to one of the world’s most iconic and demanding racing circuits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629726789/en/ From Abu Dhabi to Imola: A2RL Expands Internationally with Historic Autonomous Racing Debut at Iconic Italian Track (Photo: AETOSWire) Organized by ASPIRE, the grand challenges arm of Abu Dhabi’s Advanced Technology Research Council, A2RL has quickly evolved from a bold public testbed for AI under extreme race conditions into a competitive racing series. The upcoming Imola race marks a major step in its global expansion, following two breakthrough seasons at Yas Marina Circuit in Abu Dhabi and opening the championship’s first international chapter before it returns to the UAE capital for the 202

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release

Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in

Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release

Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye